- Home
- VMD vs ATAI Comparison
VMD vs ATAI Comparison
Compare VMD & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- ATAI
- Stock Information
- Founded
- VMD 2006
- ATAI 2018
- Country
- VMD United States
- ATAI Germany
- Employees
- VMD N/A
- ATAI N/A
- Industry
- VMD
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- VMD
- ATAI Health Care
- Exchange
- VMD Nasdaq
- ATAI Nasdaq
- Market Cap
- VMD 288.1M
- ATAI 271.6M
- IPO Year
- VMD N/A
- ATAI 2021
- Fundamental
- Price
- VMD $7.24
- ATAI $1.45
- Analyst Decision
- VMD
- ATAI Strong Buy
- Analyst Count
- VMD 0
- ATAI 4
- Target Price
- VMD N/A
- ATAI $9.00
- AVG Volume (30 Days)
- VMD 114.2K
- ATAI 2.1M
- Earning Date
- VMD 03-10-2025
- ATAI 03-17-2025
- Dividend Yield
- VMD N/A
- ATAI N/A
- EPS Growth
- VMD 12.00
- ATAI N/A
- EPS
- VMD 0.28
- ATAI N/A
- Revenue
- VMD $224,257,000.00
- ATAI $308,000.00
- Revenue This Year
- VMD $13.27
- ATAI N/A
- Revenue Next Year
- VMD $14.11
- ATAI $20.00
- P/E Ratio
- VMD $26.75
- ATAI N/A
- Revenue Growth
- VMD 22.54
- ATAI N/A
- 52 Week Low
- VMD $6.21
- ATAI $0.78
- 52 Week High
- VMD $9.81
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- VMD 36.39
- ATAI 43.24
- Support Level
- VMD $7.32
- ATAI $1.33
- Resistance Level
- VMD $7.60
- ATAI $1.48
- Average True Range (ATR)
- VMD 0.27
- ATAI 0.11
- MACD
- VMD -0.02
- ATAI -0.01
- Stochastic Oscillator
- VMD 7.59
- ATAI 43.41
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.